3//SEC Filing
Clarus Lifesciences III, L.P. 3
Accession 0000899243-20-028407
CIK 0001689548other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 8:04 PM ET
Size
29.0 KB
Accession
0000899243-20-028407
Insider Transaction Report
Form 3
Clarus Lifesciences III, L.P.
10% Owner
Holdings
- (indirect: See Footnotes)
Series B Redeemable Convertible Preferred Stock
→ Common Stock (2,361,198 underlying) - (indirect: See Footnotes)
Series C Redeemable Convertible Preferred Stock
→ Common Stock (261,318 underlying) - (indirect: See Footnotes)
Series C-1 Redeemable Convertible Preferred Stock
→ Common Stock (164,832 underlying) - (indirect: See Footnotes)
Series B-1 Redeemable Convertible Preferred Stock
→ Common Stock (659,116 underlying) - (indirect: See Footnotes)
Series C Redeemable Convertible Preferred Stock
→ Common Stock (907,378 underlying) - 700,934(indirect: See Footnotes)
Common Stock
- (indirect: See Footnotes)
Series A Redeemable Convertible Preferred Stock
→ Common Stock (3,446,711 underlying)
Footnotes (7)
- [F1]Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P.
- [F2]Reflects securities held directly by BSOF Parallel Master Fund L.P. Blackstone Strategic Opportunity Associates L.L.C. is the general partner of BSOF Parallel Master Fund L.P. Blackstone Holdings II L.P. is the sole member of Blackstone Strategic Opportunity Associates L.L.C. Blackstone Alternative Solutions L.L.C. is the investment manager of BSOF Parallel Master Fund L.P. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C.
- [F3]All series of Preferred Stock of the Issuer are convertible into common stock of the Issuer (the "Common Stock") on a 1-for-2.14 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. All series of Preferred Stock have no expiration date.
- [F4]The general partner of each of Blackstone Holdings I L.P. and Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
- [F5]Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
- [F6]Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 3.
- [F7]Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Praxis Precision Medicines, Inc.
CIK 0001689548
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001597143
Filing Metadata
- Form type
- 3
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 8:04 PM ET
- Size
- 29.0 KB